Search
 
 
Product Details
Bimatoprost,LUMIGAN,BIMATOPROST,BIMATOPROST(CAS:155206-00-1)
Bimatoprost
Bimatoprost,LUMIGAN,BIMATOPROST,BIMATOPROST(CAS:155206-00-1) treat glaucoma or ocular (eye) hypertension

Name

Bimatoprost

CAS

155206-00-1

Synonyms

N-ETHYL-9ALPHA,11ALPHA,15S-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROSTA-5Z, 13E-DIEN-1-AMIDE;LUMIGAN;BIMATOPROST;BIMATOPROST(TM);17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE;BIMATOPROST(LUMIGAN);17-phenyl-tri-norprostaglandin f2α-ethyl amide;(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]
-N-ethylhept-5-enamide

MF

C25H37NO4

MW

415.57

Others

Bimatoprost (marketed in the U.S., Canada and Europe by Allergan, under the trade name Lumigan) is a prostaglandin analog/prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes.[1] In December 2008, the indication to lengthen eyelashes was approved by the U.S. Food and Drug Administration (FDA); the cosmetic formulation of bimatoprost is sold as Latisse /ləˈtiːs/.[2] In 2008-2011, at least three case series suggested that bimatoprost has the ability to reduce adipose (fat) tissue.[3][4][5]